Terapi Tissue Plasminogen Activator untuk Stroke Iskemik Akut
DOI:
https://doi.org/10.55175/cdk.v50i3.661Keywords:
Iskemik, stroke akut, tissue plasminogen activatorAbstract
Prevalensi stroke terus meningkat setiap tahun. Penanganan kasus stroke harus dilakukan sesegera mungkin untuk memaksimalkan pemulihan serta mencegah berulang. Pada kasus stroke iskemik akut, pengobatan fibrinolitik tPA terbukti efektif. Beberapa kriteria pemberian harus dipenuhi. Pasien yang mendapat tPA harus mendapat observasi tekanan darah ketat dan memastikan tidak terjadi efek samping perdarahan. Hingga saat ini, hanya alteplase yang disetujui untuk pengobatan fibrinolitik pada pasien stroke iskemik akut. Telaah ilmiah berbasis bukti menunjukkan manfaat tPA lain. yaitu tenecteplase.
The prevalence of stroke continues to increase. To minimize brain injury, prompt management is necessary to maximize patient recovery and prevent recurrent strokes. Fibrinolytic tPA has been proven to be effective for acute ischemic stroke. Several criteria must be met before tPA administration. Patients should receive close monitoring of blood pressure and for bleeding risk. Until recently, only tPA alteplase has been approved for fibrinolytic treatment in acute ischemic stroke. Several evidence-based studies have shown the benefits of tenecteplase - another tPA - in acute ischemic stroke management.
Downloads
References
World Health Organization. The top 10 causes of death [Internet]. 2020 [cited 2022 Aug 18]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Ropper AH, Samuels MA, Klein JP, Prasad S. Adams and Victor’s principles of Neurology. 11th ed. McGraw Hill; 2019.
Menteri Kesehatan Republik Indonesia. Keputusan menteri kesehatan republik indonesi nomor HK.01.07/MENKES/394/2019 tentang pedoman nasional pelayanan kedokteran tata laksana stroke. Jakarta; 2019.
American Stroke Association. Acute ischemic stroke infographic [Internet]. 2020 [cited 2022 Aug 19]. Available from: https://www.stroke.org/en/about-stroke/types-of-stroke/ischemic-stroke-clots/ais-infographic
Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan YYF, et al. Part 11: Adult stroke. Circulation [Internet]. 2010 Nov 2 [cited 2022 Aug 19];122(SUPPL. 3). Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.110.971044
Aprianda R. Infodatin pusat data dan informasi kementerian kesehatan RI: stroke, don’t be the one. Jakarta; 2019.
Rato ML, Diógenes MJ, Sebastião A. Pharmacodynamics and pharmacokinetics of stroke therapy. In: Fonseca AC, Ferro JM, editors. Precision medicine in stroke. Cham: Springer Nature Switzerland AG; 2021. p. 41–69.
Markus H, Pereira A, Cloud G. Oxford specialist handbooks in neurology: stroke medicine. 2nd ed. Oxford: Oxford University Press; 2017.
Henderson SJ, Weitz JI, Kim PY. Fibrinolysis: Strategies to enhance the treatment of acute ischemic stroke. Vol. 16. Journal of Thrombosis and Haemostasis. Blackwell Publishing Ltd; 2018. p. 1932–40.
Grotta JC, Albers GW, Broderick JP, Kasner SE, Lo EH, Mendelow AD, et al. Stroke: Pathophysiology, diagnosis, and management. 6th ed. Elsevier; 2016.
Ross AM. Reviews new plasminogen activators: A clinical review. Vol. 22. Clin Cardiol. 1999;22(3):165-71. doi: 10.1002/clc.4960220303..
Nordt TK, Bode C. Thrombolysis: Newer thrombolytic agents and their role in clinical medicine. Vol. 89. Heart. BMJ Publishing Group; 2003. p. 1358–62.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Vol. 50. Stroke. Lippincott Williams and Wilkins; 2019. p. 344–418.
Berge E, Whiteley W, Audebert H, Marchis GM de, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I–LXII.
Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. The Lancet. 2014;384(9958):1929–35.
TNKase (tenecteplase) [Package Insert]. South San Fransisco: Genetech, Inc; 2018.
Retavase (Reteplase) [Package Insert]. North Carolina: Chiesi; 2022.
Berge E, Whiteley W, Audebert H, Marchis GM de, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I–LXII.
ACTIVASE (alteplase) [Package Insert]. San Francisco: Genentech, Inc.; 2015.
Hollist M, Au K, Morgan L, Shetty PA, Rane R, Hollist A, et al. Pediatric stroke: Overview and recent updates. Aging Dis. 2021;12(4):1043.
Denny MC, Ramadan AR, Savitz S, Grotta J. Acute stroke care. 3rd ed. Cambridge: Cambridge University Press; 2020.
Potla N, Ganti L. Tenecteplase vs. alteplase for acute ischemic stroke: A systematic review. Int J Emerg Med. 2022 Dec 1;15(1):1. doi: 10.1186/s12245-021-00399-w.
Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781–8.
Thelengana A, Radhakrishnan DM, Prasad M, Kumar A, Prasad K. Tenecteplase versus alteplase in acute ischemic stroke: Systematic review and meta-analysis. Acta Neurol Belg. 2019;119(3):359–67.
Zhong CS, Beharry J, Salazar D, Smith K, Withington S, Campbell BCV, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke. Stroke 2021;52(3):1087-1090. doi: 10.1161/STROKEAHA.120.030859.
Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: Meta-analysis of 5 randomized trials. Stroke 2019;50(8):2156–62.
Thommessen B, Næss H, Logallo N, Kvistad CE, Waje-Andreassen U, Ihle-Hansen H, et al. Tenecteplase versus alteplase after acute ischemic stroke at high age. International Journal of Stroke 2021;16(3):295–9.
Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): A phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511–9.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. New England Journal of Medicine. 2018;378(17):1573–82.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
